Summarized by Masters of Longevity from Longevity Technology.
A new statewide brain health collaboratory has been launched to coordinate research, clinical deployment, and workforce development focused on neurodegenerative disease and neuromodulation innovation.
Key Takeaways
- Rhode Island Life Science Hub and Cognito Therapeutics launched the Rhode Island Brain Health Collaboratory on 13 October 2026.
- The collaboratory will evaluate and deploy Cognito's Spectris platform across Rhode Island health systems and research partners.
- Cognito reported Spectris AD has FDA Breakthrough Device designation and expects pivotal HOPE trial results later in 2026.
